CD63 and neoplasm: developed a peptide, CP05 that specifically binds to CD63 on exosomes, and conjugating a muscle targeting peptide to CP05 showed increasing dystrophin expression and muscle function in an animal model.[200] The discovery of exosome‐guiding peptides boosts drug‐loading exosome therapies in bone regeneration,[201, 202, 203] myocardial infarction‐ischemia/reperfusion,[204] exosome source identification,[205] and chemo/photodynamic therapy enhancement.[206] Based on this, CP05 is an excellent linker between TEXs and additional molecules that can amplify anti‐tumor effects.